Latest News
Orion secures exclusive commercial licence for Abzena cancer antibody
23 October 2025 - Finnish pharmaceutical company Orion Corporation (HEL:ORNBV) and Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced on Thursday that Orion has obtained an exclusive commercial licence for one of...
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
23 October 2025 - Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Thursday that it has been granted Marketing Authorization for Ivermectin Newbury 10 mg/g cream in Denmark, marking the first approval in its Scandin...
FDA grants priority review for Merck's KEYTRUDA combinations with Padcev in muscle-invasive bladder cancer
23 October 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that the US Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License...
Sanofi expands partnership with Dassault Systèmes' Medidata to accelerate development of new therapies
23 October 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and Medidata, a Dassault Systèmes (Euronext Paris:DSY) brand, on Thursday announced an expansion of their more than 10-year collaboration to enhance clin...
BioNxt Solutions advances toward 2026 human trials for sublingual multiple sclerosis drug
23 October 2025 - Canada-based bioscience company BioNxt Solutions Inc. (CSE: BNXT, OTCQB:BNXTF, FSE: BXT) announced on Thursday that it has initiated a 15-day dosing optimisation study for its lead product, BNT23001, a proprietary sublingual Cladrib...